A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine - Trial NCT06336096
Access comprehensive clinical trial information for NCT06336096 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vertex Pharmaceuticals Incorporated and is currently Recruiting. The study focuses on Pain. Target enrollment is 72 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vertex Pharmaceuticals Incorporated
Timeline & Enrollment
Phase 1
Mar 28, 2024
Oct 01, 2024
Primary Outcome
Part A: Maximum Observed Plasma Concentration (Cmax) of SUZ,Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-tlast) of SUZ,Part A: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of SUZ,Part B: Cmax of SUZ,Part B: AUC0-tlast of SUZ,Part B: AUC0-inf of SUZ
Summary
The purpose of this study is to evaluate the pharmacokinetics (PK) of suzetrigine (SUZ;
 VX-548) and its metabolite along with its safety and tolerability, in healthy participants.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06336096
Non-Device Trial